# Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

> **NCT00502164** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Prostate Adenocarcinoma

## Interventions

- **DRUG:** AZD2171

## Key facts

- **NCT ID:** NCT00502164
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502164, "Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00502164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*